Logo do repositório
 
Publicação

Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort

2018-04-26Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorRuben, Brandão,
dc.contributor.authorRute, Marcelino,
dc.contributor.authorGoncalves, Maria de Fátima
dc.contributor.authorDiogo, Isabel
dc.contributor.authorCarvalho, A P
dc.contributor.authorCabanas, Joaquim
dc.contributor.authorCosta, Inês
dc.contributor.authorBrogueira, Pedro
dc.contributor.authorVentura, F
dc.contributor.authorMiranda , Ana Cláudia
dc.contributor.authorMansinho, Kamal
dc.contributor.authorGomes, P
dc.contributor.institutionTB, HIV and opportunistic diseases and pathogens (THOP)
dc.contributor.institutionGlobal Health and Tropical Medicine (GHTM)
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblMDPI - Multidisciplinary Digital Publishing Institute
dc.date.accessioned2021-05-03T22:39:26Z
dc.date.available2021-05-03T22:39:26Z
dc.date.issued2018-04-26
dc.description.abstractThis study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent14
dc.format.extent1462364
dc.identifier.doi10.3390/v10050223
dc.identifier.issn1999-4915
dc.identifier.otherPURE: 6140247
dc.identifier.otherPURE UUID: a3a75ce9-3a04-4d2e-a04c-91697a22e7f3
dc.identifier.otherScopus: 85046272851
dc.identifier.otherPubMed: 29701642
dc.identifier.otherPubMedCentral: PMC5977216
dc.identifier.urihttp://hdl.handle.net/10362/116851
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pubmed/29701642
dc.language.isoeng
dc.peerreviewedyes
dc.subjectDirect-acting antivirals
dc.subjectHepatitis C virus
dc.subjectNS5A
dc.subjectNS5B
dc.subjectResistance-associated substitutions
dc.subjectSDG 3 - Good Health and Well-being
dc.titleCharacterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohorten
dc.typejournal article
degois.publication.issuen.º 5
degois.publication.titleViruses
degois.publication.volumeVol. 10
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Characterization_of_NS5A_and_NS5B.pdf
Tamanho:
1.39 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IHMT: MM - Artigos em revista internacional com arbitragem científica